Gemcitabine/docetaxel-Welcome to a new standard

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 313-315

  Fleming, Gini ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; EDITORIAL; HUMAN; LEIOMYOSARCOMA; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEIOMYOSARCOMA; TAXOIDS; UTERINE NEOPLASMS;

EID: 44449159324     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.025     Document Type: Editorial

References (18)

1. Hensley M.L., Blessing J.A., DeGeest K., Abulafia O., Rose P.G., and Homesley H.D. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. Gynecol. Oncol. 109 (2008) 323-328
2. Hensley M.L., Blessing J.A., Mannel R., and Rose P.G. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 109 (2008) 329-334
3. Kanjeekal S., Chambers A., Fung M.F.K., and Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol. Oncol. 97 (2005) 624-637
4. Sutton G.P., Blessing J.A., Barret R.J., and McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Am. J. Obstet. Gynecol. Oncol. 166 (1992) 556-559
5. Sutton G., Blessing J.A., and Malfetano J.H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study. Gynecol. Oncol. 62 (1996) 226-229
6. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13 (1995) 1537-1545
7. Verweij J., Lee S.M., Ruka W., et al. Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 18 (2000) 2081-2086
8. Gallup D.G., Blessing J.A., Andersen W., et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol. Oncol. 89 (2003) 48-51
9. Van Hoesel Q.G.C.M., Verweij J., Catemil G., et al. Phase II study with docetaxel (Taxotere®) in advance soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma and Group. Ann. Oncol. 5 (1994) 539-542
10. Maki R.G. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist 12 (2007) 999-1006
11. Maki R.G., Wathen J.K., Patel S.R., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through Collaboration study 002. J. Clin. Oncol. 25 (2007) 2755-2763
12. Temporo M., Plunkett W., Ruiz Van Haperen V., et al. A randomized phase II comparison of dose-intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic carcinoma. J. Clin. Oncol. 21 (2003) 3402-3408
13. Look K.Y., Sandler A., Blessing J.A., et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomysarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol. Oncol. 92 (2004) 644-647
14. Pautier P., Genestie C., Rey A., et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88 (2000) 1425-1431
15. Judson I., Radford F.A., Harris M., et al. Randomized phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37 (2001) 870-877
16. Sutton G., Blessing J., Hanjani P., and Kramer P. Phase II evaluation of liposomal doxorobicin (Doxil) in recurrent or advance leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 96 (2005) 749-752
17. D'Adamo D.R., Keohan M., Schuetze S., et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)). J. Clin. Oncol. (2007) ASCO Annual Meeting Proceedings Supplement 25:545s abstr#10001
18. Wright J.D., Powell M.A., Rader J.S., et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 27 (2007) 3525-3528